3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
5
Philadelphia Chromosome
2
Leukemia
2
Myeloproliferative Disorders
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid
1
Hematologic Diseases
1
Interventions
fludarabine phosphate
43
Whole-Body Irradiation
36
Mycophenolic Acid
36
Peripheral Blood Stem Cell Transplantation
31
Cyclophosphamide
31
Tacrolimus
28
Busulfan
22
Antilymphocyte Serum
21
Cyclosporine
19
fludarabine
17
ruxolitinib
16
Melphalan
16
Methotrexate
15
Cytarabine
12
thymoglobulin
9
Sirolimus
9
Etoposide
9
Granulocyte Colony-Stimulating Factor
8
Filgrastim
8
Cyclosporins
8
Radiotherapy
7
Cord Blood Stem Cell Transplantation
7
Rituximab
6
Alemtuzumab
6
merphos
5
Stem Cell Transplantation
5
Flow Cytometry
5
Azacitidine
5
sargramostim
4
ponatinib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Myeloproliferative Disorders
×
asciminib
×
Clear all
NCT05456191
2026-05-27
ASC4START
Novartis
Phase 3
Active not recruiting
568 enrolled
11 charts